THMO
Cesca Therapeutics Inc is engaged in the development and manufacturing of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products.
ThermoGenesis Holdings, Inc. (THMO) is rated C- (2.1/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-07-29 | C+ (2.5) | C (2.3) | C- (1.9) | C (2.2) | D+ (1.5) | C- (2.1) |
| 2024-03-31 | C+ (2.5) | C (2.5) | C (2.2) | C- (2.1) | D+ (1.5) | C (2.2) |
| 2023-09-30 | C+ (2.5) | C (2.3) | D (1.4) | C (2.3) | D (1.5) | C- (2.0) |
| 2023-06-30 | C+ (2.5) | D (1.3) | C- (2.0) | C (2.3) | D (1.5) | C- (1.9) |
| 2023-03-31 | C+ (2.5) | C- (1.9) | C (2.3) | C (2.3) | D (1.5) | C- (2.1) |